Long-standing debate over metformin's primary target resolved by new findings

Researchers have identified the main mechanism of the widely used diabetes drug metformin, settling a long-standing question about whether it acts primarily in the intestines or the liver. The new evidence points to the intestines as the key site of action, clarifying how the medication lowers blood sugar. This insight could inform future diabetes treatments and drug development.

Metformin has been a cornerstone of diabetes treatment for decades, yet its precise biological mechanism remained unsettled. Researchers have now identified the intestines as the drug's primary site of action, resolving a long-standing scientific debate over whether the liver or gut was the main target. This clarification explains more precisely how metformin achieves its blood-sugar-lowering effects.

The finding carries practical implications for pharmaceutical research. Understanding where and how metformin works could guide the development of more targeted diabetes therapies, potentially improving efficacy while reducing side effects. The resolution of this mechanistic question also demonstrates how basic biological research continues to refine our understanding of even well-established medications.